These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9598423)

  • 1. Testing simultaneous hypotheses in pharmaceutical trials: a Bayesian approach.
    Dominici F
    J Biopharm Stat; 1998 May; 8(2):283-97. PubMed ID: 9598423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios.
    Yin G; Li Y; Ji Y
    Biometrics; 2006 Sep; 62(3):777-84. PubMed ID: 16984320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A hybrid Bayesian-frequentist approach to evaluate clinical trial designs for tests of superiority and non-inferiority.
    Shao Y; Mukhi V; Goldberg JD
    Stat Med; 2008 Feb; 27(4):504-19. PubMed ID: 17854052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing noninferiority in a three-arm trial using the Bayesian approach.
    Ghosh P; Nathoo F; Gönen M; Tiwari RC
    Stat Med; 2011 Jul; 30(15):1795-808. PubMed ID: 21520456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Bayesian design and analysis for dose-response using informative prior information.
    Smith MK; Marshall S
    J Biopharm Stat; 2006; 16(5):695-709. PubMed ID: 17037266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sure outcomes of random events: a model for clinical trials.
    Bouckaert A; Mouchart M
    Stat Med; 2001 Feb; 20(4):521-43. PubMed ID: 11223899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
    Gerke O; Siedentop H
    Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-dimensional dose finding in discrete dose space.
    Wang K; Ivanova A
    Biometrics; 2005 Mar; 61(1):217-22. PubMed ID: 15737096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A hybrid Bayesian adaptive design for dose response trials.
    Chang M; Chow SC
    J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detecting potential safety issues in clinical trials by Bayesian screening.
    Gould AL
    Biom J; 2008 Oct; 50(5):837-51. PubMed ID: 18932142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous testing of noninferiority and superiority increases the false discovery rate.
    Ng TH
    J Biopharm Stat; 2007; 17(2):259-64. PubMed ID: 17365222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptive Bayesian design for phase I dose-finding trials using a joint model of response and toxicity.
    Wang M; Day R
    J Biopharm Stat; 2010 Jan; 20(1):125-44. PubMed ID: 20077253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Bayesian evaluation of enrolling additional patients at the maximum tolerated dose in Phase I trials.
    Gönen M
    Contemp Clin Trials; 2005 Apr; 26(2):131-40. PubMed ID: 15837436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: a tutorial.
    Zohar S; Teramukai S; Zhou Y
    Contemp Clin Trials; 2008 Jul; 29(4):608-16. PubMed ID: 18201945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Bayesian predictive two-stage design for phase II clinical trials.
    Sambucini V
    Stat Med; 2008 Apr; 27(8):1199-224. PubMed ID: 17763528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control.
    Tighiouart M; Rogatko A; Babb JS
    Stat Med; 2005 Jul; 24(14):2183-96. PubMed ID: 15909291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypothesis testing and Bayesian estimation using a sigmoid Emax model applied to sparse dose-response designs.
    Thomas N
    J Biopharm Stat; 2006; 16(5):657-77. PubMed ID: 17037264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using a reliability process to reduce uncertainty in predicting crashes at unsignalized intersections.
    Haleem K; Abdel-Aty M; Mackie K
    Accid Anal Prev; 2010 Mar; 42(2):654-66. PubMed ID: 20159091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bayesian dose finding design for dual endpoint phase I trials.
    Loke YC; Tan SB; Cai Y; Machin D
    Stat Med; 2006 Jan; 25(1):3-22. PubMed ID: 16013039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sample-size calculations for trials that inform individual treatment decisions: a 'true-choice' approach.
    Girling AJ; Lilford RJ; Braunholtz DA; Gillett WR
    Clin Trials; 2007; 4(1):15-24. PubMed ID: 17327242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.